Navigation Links
Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
Date:7/21/2008

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, July 21 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company announces that non-executive director Robin Buchanan, due to his other commitments, will step down from the Board of Directors on 29 July 2008 on the completion of his term of office.

The Board thanks Mr. Buchanan for his many contributions during his five years with the Company.

Notes to Editors

Shire Limited

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGFb3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

For further information please contact:

Investor Relations: Clea Rosenfeld (Rest of the World), +44-1256-894-160

Eric Rojas (North America), +1-484-595-8252

Media: Jessica Mann (Rest of the World), +44-1256-894-280

Matthew Cabrey (North America), +1-484-595-8248

Jessica Cotrone (North America), +1-617-613-4640


'/>"/>
SOURCE Shire Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
2. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
3. Application for Listing of Shire Limited Ordinary Shares
4. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
5. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
6. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
7. New Shire Holding Company Proposal
8. Shire to Introduce a New UK Listed Holding Company
9. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
10. Shire plc: Long Term Incentive Plan
11. Shire plc: IFRS Results for the Year Ending December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new ... rates in frozen and fresh in vitro fertilization (IVF) transfer cycles. ... to IVF success. , After comparing the results from the fresh and frozen ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:8/23/2017)... 23, 2017  The general public,s help is being enlisted in what,s ... live in and on the human body –and are believed to affect ... The Microbiome Immunity Project is ... starting with the gut. The project's goal is to help advance scientific ... ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
Breaking Biology News(10 mins):